Eli Lilly Shares Rise After FDA Clears Once-Daily Oral Obesity Drug Foundayo
Eli Lilly shares climbed 4% after the FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 therapy for weight loss. The approval makes Foundayo Lilly's second FDA-cleared obesity medication and establishes commercial availability through LillyDirect and, later, U.S. pharmacies and telehealth providers. Clinical trials showed substantial av…